All In Biotech

Drug Trial Radar · NCT07739485

Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study

A Dose-Finding Study of Paclitaxel Oral Solution in Neoadjuvant Therapy for Patients With Triple Negative Breast Cancer

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Jul 30, 2027

Study completion Jul 30, 2029

Sponsor

Lead sponsor
Liu ShuAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, dose-escalation trial using a backfill Bayesian optimal interval (BF-BOIN) design to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) for paclitaxel oral solution followed by epirubicin plus cyclophosphamide therapy. Eligible triple-negative breast cancer patients are enrolled in three cohorts at oral paclitaxel dose levels 1-3 (125, 150, 175 mg/m²).

Conditions

  • Triple -Negative Breast Cancer

Interventions

  • Epirubicin and cyclophosphamide followed by paclitaxel oral solutionDrug

    Cycles 1-4: Epirubicin 90 mg/m² plus cyclophosphamide 600 mg/m² by intravenous infusion on day 1 (D1) of each cycle; one treatment cycle administered every 2 weeks. Cycles 5-8: Paclitaxel oral solution 125, 150, or 175 mg/m², given twice daily on days 1, 8, and 15 of each cycle; one cycle every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose(MTD)Time frame: Up to approximately 30 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.